logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Etrolizumab for treating moderately to severely active ulcerative colitis in adults

< Back

Etrolizumab for treating moderately to severely active ulcerative colitis in adults

Drugs

Gastrointestinal, Pancreatic and Liver Disease

June 2020


Etrolizumab is in clinical development for the treatment of adult patients with moderately to severely active ulcerative colitis. Ulcerative colitis is a long-term condition where the colon and rectum (parts of the bowel), become inflamed. Small ulcers can develop on the colon’s lining, which can cause rectal bleeding and recurring diarrhoea. The symptoms of ulcerative colitis often follow a pattern where individuals with the condition have periods of no symptoms or mild symptoms (remission) followed by periods where their symptoms are particularly troublesome (flare-ups or relapses).

Etrolizumab is a new monoclonal antibody (an immune protein) delivered by subcutaneous injection. The treatment works by targeting molecules called integrins to control the immune response and prevent the accumulation of immune molecules, which cause inflammation in individuals with a form of ulcerative colitis where inflammation is not mediated by a signalling protein called tumour necrosis factors (TNF) alpha (‘non-TNF-α’) and who are therefore intolerant to TNF blockers. This represents a new target group as current therapies focus mainly on anti-TNF inflammation. In one study, etrolizumab showed a greater reduction of intestinal lymphocyte infiltration in comparison to standard treatment.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts